Bayer is trading 4.4% higher at €54.12 after Q3 results beat analyst expectations.
- Pharma sales grew and exceeded forecasts; Q3 sales and adjusted EBITDA also beat expectations. Bayer raised its full-year outlook for pharma margin, group EBITDA and free cash flow.
- After a sharp gain in the prior session, Bayer still reported a quarterly net loss and has substantial debt. No trading-volume data is available.